Background
Phase II, open-label RCT (Intergroup E4412). 147 patients with relapsed or refractory classical Hodgkin lymphoma in the salvage setting, enrolled regardless of prior BV exposure (though most were BV-naive). The trial tested whether adding ipilimumab (anti-CTLA-4) to BV+nivolumab could improve outcomes, particularly deep remissions allowing durable disease control without stem cell transplantation.
Interventions and follow up
Arm A: BV 1.8 mg/kg + nivolumab 3 mg/kg q3w × 4 cycles (n=66)
Arm B: BV 1.8 mg/kg + nivolumab 3 mg/kg + ipilimumab 1 mg/kg q3w × 4 cycles (n=66)
Primary endpoint: CR rate after 4 cycles
Median follow up: ~3 years
Arm B: BV 1.8 mg/kg + nivolumab 3 mg/kg + ipilimumab 1 mg/kg q3w × 4 cycles (n=66)
Primary endpoint: CR rate after 4 cycles
Median follow up: ~3 years
Results
CR rate (BV/nivo vs. BV/nivo/ipi): 64.7% vs. 70.3% — not significantly different
ORR: 80.0% vs. 86.1%
36-mo PFS (patients NOT proceeding to SCT): 45.8% (BV/nivo) vs. 73.0% (BV/nivo/ipi), HR 0.45, P=.03 — triplet signal for SCT deferral
36-mo PFS (all patients): no significant overall difference
ORR: 80.0% vs. 86.1%
36-mo PFS (patients NOT proceeding to SCT): 45.8% (BV/nivo) vs. 73.0% (BV/nivo/ipi), HR 0.45, P=.03 — triplet signal for SCT deferral
36-mo PFS (all patients): no significant overall difference
Adverse events
Grade ≥3 AEs: BV/nivo/ipi 57% vs. BV/nivo 44%
Immune-mediated (grade ≥3, higher with ipilimumab): colitis 12%, hepatitis 9%, pneumonitis 6%
Other: BV peripheral neuropathy any grade ~40% both arms; treatment-related discontinuations higher with triplet; no treatment-related deaths in either arm
Immune-mediated (grade ≥3, higher with ipilimumab): colitis 12%, hepatitis 9%, pneumonitis 6%
Other: BV peripheral neuropathy any grade ~40% both arms; treatment-related discontinuations higher with triplet; no treatment-related deaths in either arm
Conclusions
Addition of ipilimumab to BV+nivolumab did not significantly improve CR rate overall in R/R cHL, but showed a signal of improved 36-month PFS (73% vs. 46%) in patients not proceeding to stem cell transplantation — suggesting the triplet may achieve more durable disease control in patients managed without transplant. Higher immune toxicity limits broad applicability.
Key Limitations
Underpowered Phase 2 trial (N=66 per arm) with a CR-rate primary endpoint that did not discriminate between arms; the PFS benefit in the non-SCT subgroup is hypothesis-generating, not confirmatory, and may reflect post-hoc selection bias (patients who did not proceed to SCT had different disease biology). Grade ≥3 immune AEs significantly higher with triplet (colitis 12%, hepatitis 9%). No randomized comparison to pembro-GVD or other salvage regimens. Published in Blood 2026, the most recent evidence at time of this entry.
Clinical Context
E4412 suggests the BV/nivo/ipi triplet may offer durable disease control as an alternative to SCT consolidation in selected R/R cHL patients, with a signal of improved PFS in those not undergoing transplant, aligning with broader interest in transplant-free strategies using PD-1/CTLA-4 combinations. The triplet is not an established standard; single-agent pembrolizumab and BV+nivolumab carry FDA approval/widespread use in R/R cHL, and pembro-GVD remains a preferred bridging option. A confirmatory Phase 3 trial would be needed.